Skip to main content
OpenTrials

Clinical trial condition

Lymphatic Diseases

Explore clinical trials studying Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

9,012 public trials 1,844 recruiting studies
Refine in advanced search Browse all conditions

Lymphatic Diseases trial results

Completed

A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis

NCT01395004

Conditions
Hemic and Lymphatic Diseases, Histiocytosis, Histiocytosis, Langerhans-Cell, +5 more
Locations
  • Johns Hopkins Hospital Baltimore, Maryland, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Staten Island University Hospital Staten Island, New York, United States
View Trial Details
Completed

Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma

NCT02590263

Conditions
Astrocytoma, Glioblastoma, Glioblastoma Multiforme, +17 more
Locations
  • Nagoya University Hospital /ID# 138559 Nagoya, Aichi-ken, Japan
  • Hiroshima University Hospital /ID# 139399 Hiroshima, Japan
  • Hokkaido University Hospital /ID# 150589 Sapporo, Hokkaido, Japan
  • University of Tsukuba Hospital /ID# 140433 Tsukuba, Ibaraki, Japan
View all 22 locations
View Trial Details
Completed

A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma

NCT00718419

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Boston, Massachusetts, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. La Roche-sur-Yon, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Nantes, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Nîmes, France
View Trial Details
Completed

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

NCT02945215

Conditions
B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Beijing cancer hospital Beijing, Beijing Municipality, China
  • Peking University third hospital Beijing, Beijing Municipality, China
  • The 307th Hospital of Military Medical Sciences Beijing, Beijing Municipality, China
  • Harbin Medical University Cancer Hospital Haerbin, Heilongjiang, China
View Trial Details

Related conditions